Market Overview

UPDATE: J.P. Morgan Initiates Coverage on AbbVie with Neutral Rating, $38 PT

Share:
Related ABBV
AbbVie Initiates Pivotal Phase 3 Study of Veliparib for Patients with Early-Stage Triple-Negative Breast Cancer
Enanta Pharmaceuticals Announces Additional Data from AbbVie's M13-393 Study to be Presented at Liver Meeting
Tactical Dividend Growth: Buying Biotech, Assessing Market Volatility (Seeking Alpha)

In a report published Wednesday, J.P. Morgan & Co. initiated coverage on AbbVie (NYSE: ABBV) with a Neutral rating and $38.00 price target.

J.P. Morgan noted, “We are initiating coverage of ABBV shares with a Neutral rating and $38 YE'13 price target. We see AbbVie as essentially a Humira story until the company is able to further diversify its business. While Humira is a well-positioned franchise and we are above the Street with our estimates over the next several years, we do not see ABBV shares getting credit for these results given the longer-term competitive threats facing the product. Rather, we believe portfolio diversification will be a key driver of multiple expansion and outperformance for the stock, and this remains several years away, in our view.”

AbbVie closed on Monday at $34.16.

Latest Ratings for ABBV

DateFirmActionFromTo
Jul 2015Deutsche BankMaintainsBuy
Jul 2015SunTrust Robinson HumphreyInitiates Coverage onBuy
Jun 2015Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Initiation Analyst Ratings

 

Related Articles (ABBV)

View Comments and Join the Discussion!

Get Benzinga's Newsletters